Cargando…

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels

BACKGROUND: Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite the high inter-patient variability in pharmacokinetic exposure, pazopanib is administered at a fixed dose of 800 mg once daily (QD). Pharmacokinetic exposure is l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groenland, Stefanie L., Katz, Daniela, Huitema, Alwin D. R., Steeghs, Neeltje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276240/ https://www.ncbi.nlm.nih.gov/pubmed/30509247 http://dx.doi.org/10.1186/s12885-018-5043-9

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma
por: Pisano, Sorana G., et al.
Publicado: (2019)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
por: Hong, Jung Yong, et al.
Publicado: (2023)

Therapeutic drug monitoring of oral targeted antineoplastic drugs
por: Mueller-Schoell, Anna, et al.
Publicado: (2020)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review
por: van Dyk, Madelé, et al.
Publicado: (2022)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
por: Shido, Yoji, et al.
Publicado: (2017)

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
por: Ray-Coquard, Isabelle, et al.
Publicado: (2017)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study
por: Mirili, Cem, et al.
Publicado: (2019)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p843ec099veov90jo4egu40q7m